ArticleAnnals of hematology2025

Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).

Anne Quinquenel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.